Granite Point Capital Management L.P. Has $254,000 Position in SCYNEXIS, Inc. (SCYX)
Granite Point Capital Management L.P. maintained its stake in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 141,750 shares of the company’s stock at the end of the 2nd quarter. Granite Point Capital Management L.P. owned approximately 0.55% of SCYNEXIS worth $254,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of SCYX. Federated Investors Inc. PA grew its holdings in SCYNEXIS by 23.5% in the 2nd quarter. Federated Investors Inc. PA now owns 4,208,400 shares of the company’s stock valued at $7,533,000 after buying an additional 800,040 shares in the last quarter. Private Advisor Group LLC purchased a new stake in SCYNEXIS in the 1st quarter valued at $555,000. KCG Holdings Inc. purchased a new stake in SCYNEXIS in the 1st quarter valued at $416,000. Dynamic Technology Lab Private Ltd purchased a new stake in SCYNEXIS in the 1st quarter valued at $154,000. Finally, Iguana Healthcare Management LLC grew its holdings in SCYNEXIS by 20.0% in the 1st quarter. Iguana Healthcare Management LLC now owns 300,000 shares of the company’s stock valued at $828,000 after buying an additional 50,000 shares in the last quarter. Institutional investors own 36.75% of the company’s stock.
Several analysts have issued reports on the company. Zacks Investment Research cut SCYNEXIS from a “buy” rating to a “hold” rating in a report on Wednesday, September 6th. ValuEngine upgraded SCYNEXIS from a “strong sell” rating to a “sell” rating in a report on Friday, July 14th. Roth Capital assumed coverage on SCYNEXIS in a report on Monday, July 10th. They issued a “buy” rating and a $8.50 target price for the company. Finally, HC Wainwright set a $14.00 target price on SCYNEXIS and gave the company a “buy” rating in a report on Wednesday, August 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $10.25.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/granite-point-capital-management-l-p-has-254000-position-in-scynexis-inc-scyx/1561556.html.
SCYNEXIS, Inc. (SCYX) traded up 1.4364% during trading on Thursday, hitting $2.2316. The stock had a trading volume of 37,856 shares. The firm’s market cap is $59.63 million. The stock’s 50-day moving average is $1.79 and its 200 day moving average is $2.12. SCYNEXIS, Inc. has a one year low of $1.52 and a one year high of $5.51.
In related news, Director David C. Hastings purchased 20,000 shares of the business’s stock in a transaction dated Wednesday, June 21st. The stock was bought at an average cost of $1.75 per share, with a total value of $35,000.00. Following the completion of the acquisition, the director now directly owns 20,000 shares in the company, valued at approximately $35,000. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders bought 45,000 shares of company stock valued at $75,850. Insiders own 3.91% of the company’s stock.
SCYNEXIS Company Profile
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Want to see what other hedge funds are holding SCYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SCYNEXIS, Inc. (NASDAQ:SCYX).
Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.